Tag

Revolution Medicines

7 stories

FDA Apr 18, 2026

RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25

Revolution Medicines' pan-RAS inhibitor delivered a landmark Phase 3 survival readout at AACR25 that doubled survival, setting off what the oncology field…

Deals Apr 17, 2026

Topped $30B: Revolution Medicines Buyout Climbs on Cancer Win

Revolution Medicines had a rumored $30 billion buyout offer on the table in January.

Deals Apr 16, 2026

Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win

Revolution Medicines is raising $2 billion in a stock offering priced at $142 per share, up from the $1 billion it announced Monday, hours after reporting…

Deals Apr 16, 2026

Revolution Medicines Prices Record Raise, Biotech's Biggest Since Pandemic

Revolution Medicines just priced a public equity raise, the largest single biotech offering since the Covid-19 pandemic.

FDA Apr 14, 2026

Doubles PDAC Survival: Revolution Jumps 40% on Daraxonrasib Phase 3 Data

Revolution Medicines shares jumped to $134.80 Monday, up nearly 40%, after daraxonrasib delivered overall survival of 13.2 months in metastatic pancreatic…

FDA Apr 13, 2026

Revolution Medicines' Daraxonrasib Succeeds in Phase 3 Registrational Trial

Daraxonrasib succeeded in a Phase 3 registrational trial for pancreatic cancer patients, Revolution Medicines reported Monday.

FDA Apr 13, 2026

Cleared Phase 3: Daraxonrasib Hits 13.2-Month OS in Pancreatic Cancer

Daraxonrasib cleared both primary endpoints in a phase 3 trial for previously treated metastatic pancreatic cancer, Revolution Medicines reported April 13.